[Generation of a New Strain of NOD/SCID/IL2Rγ Mice with Targeted Disruption of Prkdc and IL2Rγ Genes Using CRISPR/Cas9 System]

Overview

Journal Nan Fang Yi Ke Da Xue Xue Bao

Specialty General Medicine

Date 2018 Jul 13

PMID 29997084

Citations 2

Authors

Ya-Chen Liu

Qu Chen

Xing-Long Yang

Qing-Shuang Tang

Kai-Tai Yao

Yang Xu

Affiliations

Soon will be listed here.

Abstract

Objective: The NOD/SCID/IL2Rγ (NSG) mouse strain is the most widely used immunodeficient strain for xenograft transplantation. However, the existing SCID mutation is a spontaneous mutation of the Prkdc gene, which leads to leaky T cell developmental block and difficulty in genotyping. It is therefore important to develop a new strain of NSG mice with targeted disruption of Prkdc and IL2Rγ genes.

Methods: Targeted disruption of Prkdc and IL2Rγ genes was achieved using the CRISPR/Cas9 system. By intercrossing the knockout and NOD mice, we obtained a novel strain of NOD/SCID/IL2Rγ(NSG) mice, denoted as cNSG (Chinese NSG) mice.

Results: In addition to the NOD mutation, cNSG mice exhibited a complete absence of T cells, B cells and NK cells. cNSG mice allowed more efficient engraftment of human cancer cells than the commonly used immunodeficient nude mice.

Conclusion: cNSG mice will provide an important xenotransplantation model for biomedical research.

Citing Articles

Contemporary preclinical mouse models for pediatric rhabdomyosarcoma: from bedside to bench to bedside.

Martynov I, Dhaka L, Wilke B, Hoyer P, Vahdad M, Seitz G Front Oncol. 2024; 14:1333129.

PMID: 38371622 PMC: 10869630. DOI: 10.3389/fonc.2024.1333129.

Experimental Murine Models for Colorectal Cancer Research.

Neto I, Rocha J, Gaspar M, Reis C Cancers (Basel). 2023; 15(9).

PMID: 37174036 PMC: 10177088. DOI: 10.3390/cancers15092570.

References

Sung Y, Baek I, Kim D, Jeon J, Lee J, Lee K . Knockout mice created by TALEN-mediated gene targeting. Nat Biotechnol. 2013; 31(1):23-4. DOI: 10.1038/nbt.2477. View

Wang H, Yang H, Shivalila C, Dawlaty M, Cheng A, Zhang F . One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell. 2013; 153(4):910-8. PMC: 3969854. DOI: 10.1016/j.cell.2013.04.025. View

Mombaerts P, Iacomini J, Johnson R, Herrup K, Tonegawa S, Papaioannou V . RAG-1-deficient mice have no mature B and T lymphocytes. Cell. 1992; 68(5):869-77. DOI: 10.1016/0092-8674(92)90030-g. View

Yamauchi T, Takenaka K, Urata S, Shima T, Kikushige Y, Tokuyama T . Polymorphic Sirpa is the genetic determinant for NOD-based mouse lines to achieve efficient human cell engraftment. Blood. 2013; 121(8):1316-25. DOI: 10.1182/blood-2012-06-440354. View

Christianson S, Greiner D, Hesselton R, Leif J, Wagar E, Schweitzer I . Enhanced human CD4+ T cell engraftment in beta2-microglobulin-deficient NOD-scid mice. J Immunol. 1997; 158(8):3578-86. View

Shinkai Y, Rathbun G, Lam K, Oltz E, Stewart V, Mendelsohn M . RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell. 1992; 68(5):855-67. DOI: 10.1016/0092-8674(92)90029-c. View

Cao X, Shores E, Hu-Li J, Anver M, Kelsall B, Russell S . Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity. 1995; 2(3):223-38. DOI: 10.1016/1074-7613(95)90047-0. View

Shultz L, Schweitzer P, Christianson S, Gott B, Schweitzer I, Tennent B . Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol. 1995; 154(1):180-91. View

Ran F, Hsu P, Wright J, Agarwala V, Scott D, Zhang F . Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013; 8(11):2281-2308. PMC: 3969860. DOI: 10.1038/nprot.2013.143. View

10.

Bosma G, CUSTER R, Bosma M . A severe combined immunodeficiency mutation in the mouse. Nature. 1983; 301(5900):527-30. DOI: 10.1038/301527a0. View

11.

Shultz L, Brehm M, Garcia-Martinez J, Greiner D . Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol. 2012; 12(11):786-98. PMC: 3749872. DOI: 10.1038/nri3311. View

12.

Leijon K, Hammarstrom B, Holmberg D . Non-obese diabetic (NOD) mice display enhanced immune responses and prolonged survival of lymphoid cells. Int Immunol. 1994; 6(2):339-45. DOI: 10.1093/intimm/6.2.339. View

13.

Takenaka K, Prasolava T, Wang J, Mortin-Toth S, Khalouei S, Gan O . Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat Immunol. 2007; 8(12):1313-23. DOI: 10.1038/ni1527. View

14.

Shultz L, Ishikawa F, Greiner D . Humanized mice in translational biomedical research. Nat Rev Immunol. 2007; 7(2):118-30. DOI: 10.1038/nri2017. View

15.

Shultz L, Lyons B, Burzenski L, Gott B, Chen X, Chaleff S . Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005; 174(10):6477-89. DOI: 10.4049/jimmunol.174.10.6477. View

16.

Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G . Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood. 2005; 106(5):1565-73. PMC: 1895228. DOI: 10.1182/blood-2005-02-0516. View

17.

Yahata T, Ando K, Nakamura Y, Ueyama Y, Shimamura K, Tamaoki N . Functional human T lymphocyte development from cord blood CD34+ cells in nonobese diabetic/Shi-scid, IL-2 receptor gamma null mice. J Immunol. 2002; 169(1):204-9. DOI: 10.4049/jimmunol.169.1.204. View

18.

Li F, Cowley D, Banner D, Holle E, Zhang L, Su L . Efficient genetic manipulation of the NOD-Rag1-/-IL2RgammaC-null mouse by combining in vitro fertilization and CRISPR/Cas9 technology. Sci Rep. 2014; 4:5290. PMC: 4894429. DOI: 10.1038/srep05290. View

19.

Sommer D, Peters A, Wirtz T, Mai M, Ackermann J, Thabet Y . Efficient genome engineering by targeted homologous recombination in mouse embryos using transcription activator-like effector nucleases. Nat Commun. 2014; 5:3045. DOI: 10.1038/ncomms4045. View

20.

Ueda T, Tsuji K, Yoshino H, Ebihara Y, Yagasaki H, Hisakawa H . Expansion of human NOD/SCID-repopulating cells by stem cell factor, Flk2/Flt3 ligand, thrombopoietin, IL-6, and soluble IL-6 receptor. J Clin Invest. 2000; 105(7):1013-21. PMC: 377479. DOI: 10.1172/JCI8583. View